http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012329875-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a685c56ebc75cacfe0eb94b08da403ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3eaed70713265977c5c4d4c5b51efe07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de7c1a8154681def36fc24277647ce75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a33c2b4ed2ad40fef7bf9029b51dac1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66bf9241573049a8f547817507011e90
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
filingDate 2012-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98f41b1a4de0d050188a69c2df151a80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_005b1c506a493dfbb8b2d56cec5c59d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71a741a10d2bb6c1c76d87bdf602aa61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33246251700242983a47e8410b4cb5c4
publicationDate 2012-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2012329875-A1
titleOfInvention Ibuprofen for Topical Administration
abstract Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl) propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11007161-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10596117-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10561627-B2
priorityDate 2008-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008063607-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396577
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396472
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16666
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226817970
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409326
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129001639
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66705995
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID229806594
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406017
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226433620
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18939913
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406018
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7107
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128141410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31236
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226590190
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID17848643
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5364430
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24699
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226427931
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412365
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7175
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226440158
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396296
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395574
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2682
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8221
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7456
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128732144
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19069476
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID39912
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3672
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395293
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14985
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395153
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128483776
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1254
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2758
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395359
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5363269
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393858
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87581099
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406050
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11557370
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395152
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23618872
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22628260
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396434
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396576
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227610165

Total number of triples: 81.